FDA Finalizes Bemotrizinol, First New US Sunscreen Filter in 25 Years

The Food and Drug Administration finalized its approval of bemotrizinol on June 9, 2026, clearing the broad-spectrum ultraviolet filter for use in US sunscreens. It is the first new sunscreen active ingredient added to the federal monograph since 1999, ending a 25-year stretch in which American formulators worked from a frozen palette while Europe and Asia adopted a generation of better filters. The ingredient, sold by dsm-firmenich under the brand name Parsol Shield, was approved at concentrations up to 6 percent.

The decision turns a long-anticipated proposal into law. The FDA issued a proposed administrative order in December 2025, took public comment through late January, and has now finalized the order under the modernized review framework established by the CARES Act. The order takes effect August 9, 2026.

Why US Sunscreens Have Lagged on UVA

The gap bemotrizinol fills is specific: UVA. Traditional US sunscreens block UVB efficiently, the radiation that causes visible sunburn. They are weaker against UVA, the longer wavelengths that penetrate deeper, drive photoaging, suppress local immune function, and contribute to skin cancer. Until this approval, avobenzone was the only non-mineral filter in the US that offered meaningful UVA coverage, and it has a flaw: it degrades under sunlight, losing potency exactly when exposure peaks.

The consequence shows up in the numbers. Peer-reviewed research from the Environmental Working Group found US sunscreens deliver, on average, just 24 percent of the UVA protection implied by their SPF labels. A consumer reaching for a high-SPF product often receives a fraction of the UVA defense they assume they are buying. Bemotrizinol has circulated in European and Asian sunscreens since 1999 under names including Tinosorb S and Parsol Shield, giving it a 27-year safety record abroad, though several of those jurisdictions apply lighter data requirements than the FDA.

What Does the Safety Data Actually Show?

The FDA cleared bemotrizinol as generally recognized as safe and effective after reviewing clinical and toxicology data. At concentrations up to 6 percent, skin absorption stayed below the agency's threshold for systemic exposure, a two-year dermal animal study found no carcinogenic effect, and a multigenerational reproductive study found no harm to offspring. Skin irritation testing showed no irritation at permitted concentrations.

That profile stands in contrast to older chemical filters. Oxybenzone, by comparison, was detected in blood at 515 times the FDA's concern threshold after a single weekend of application. The clinical program dsm-firmenich submitted enrolled nearly 500 participants chosen to represent the diversity of the US population, and the European Union's Scientific Committee on Consumer Safety reached the same safety conclusions as far back as 1999.

Beyond the safety case, the chemistry matters for daily wear. Bemotrizinol is a triazine filter that absorbs across both UVB and UVA, and it is photostable, holding its structure under sun exposure rather than breaking down like avobenzone. It can also be combined with zinc oxide to deliver broad-spectrum coverage with less of the white cast that makes mineral sunscreens unworkable for many skin tones.

When Will Bemotrizinol Reach Store Shelves?

Not immediately. The approval grants dsm-firmenich 18 months of exclusive US marketing rights for its Parsol Shield formulation, starting when the order takes effect on August 9, 2026. During that window, only products using dsm-firmenich's version can carry the ingredient. After it closes, other manufacturers may formulate with bemotrizinol, which should widen availability and pressure pricing. Shoppers will eventually find it listed as "bemotrizinol," "BEMT," or by its standardized name, bis-ethylhexyloxyphenol methoxyphenyl triazine.

The approval is narrow in one sense. Even with bemotrizinol added, US formulators will have access to 16 approved UV filters, against roughly 30 available to their European counterparts. The FDA proposed broader sunscreen reforms in 2019 and 2021, including stronger UVA standards and updated labeling, and none has been finalized. Manufacturers of other internationally available filters have largely declined to submit the safety data the agency requires, leaving the US monograph thinner than its overseas equivalents.

For now, the practical guidance is unchanged. Stable, balanced broad-spectrum protection from zinc oxide remains the most reliable option on US shelves, and bemotrizinol is an addition to that toolkit rather than a replacement. The shift it represents is structural: a regulatory system that had not moved in a generation finally did, and the filter that closes the UVA gap is on its way. For readers who treat photoprotection as the foundation of any serious routine, the arrival of a photostable UVA filter is the most consequential sunscreen news in decades.

For the underlying chemistry and photostability evidence, see our explainer on bemotrizinol and how it works. To understand why UVA matters for long-term skin health, read our breakdown of how UV radiation degrades collagen, and to make sense of the labels themselves, see how to read a sunscreen label.

Sources: dsm-firmenich press release, Environmental Working Group, and the FDA press announcement.